ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

Firm Begins Phase II Trial Of LDP-341 For Myeloma.

March 30, 2001

Harvard Physician Whose Cancer Was Spread Through Morcellation Seeks to Revamp FDA Regulation of Medical Devices

July 4, 2014

NCI To Lose 382 Cancer FTEs; DCE Board Gets Response From Sullivan, But No Promises

July 21, 1989

Adherez Issued U.S. Patent for Catenin Molecule Inhibition.

July 4, 2003

ACS Offers New Grants to Physicians

September 7, 1984

Also in this 8-page issue: White House appoints Koch Industries executive David Koch to the National Cancer Advisory Board. He asks: “How can we make the NCI elephant dance like a ballerina?”

September 17, 2004